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ABSTRACT
Objectives: We examined the use of low (<400 μg/
day, including no use) and high folic acid supplement
(FAS) dosages (≥1000 μg/day) among pregnant
women in Spain, and explored factors associated with
the use of these non-recommended dosages.
Design: Population-based cohort study.
Setting: Spain.
Participants: We analysed data from 2332 pregnant
women of the INMA study, a prospective mother-child
cohort study in Spain.
Main outcome measures: We assessed usual
dietary folate and the use of FAS from preconception
to the 3rd month (first period) and from the 4th to the
7th month (second period), using a validated food
frequency questionnaire. We used multinomial logistic
regression to estimate relative risk ratios (RRRs).
Results: Over a half of the women used low dosages
of FAS in the first and second period while 29% and
17% took high dosages of FAS, respectively. In the first
period, tobacco smoking (RRR=1.63), alcohol intake
(RRR=1.40), multiparous (RRR=1.44), unplanned
pregnancy (RRR=4.20) and previous spontaneous
abortion (RRR=0.58, lower use of high FAS dosages
among those with previous abortions) were significantly
associated with low FAS dosages. Alcohol consumption
(RRR=1.42), unplanned pregnancy (RRR=2.66) and
previous spontaneous abortion (RRR=0.68) were
associated with high dosage use. In the second period,
only tobacco smoking was significantly associated with
high FAS dosage use (RRR=0.67).
Conclusions: A high proportion of pregnant women
did not reach the recommended dosages of FAS in
periconception and a considerable proportion also used
FAS dosages ≥1000 μg/day. Action should be planned
by the Health Care System and health professionals to
improve the appropriate periconceptional use of FAS,
taking into consideration the associated factors.
BACKGROUND
The beneﬁts of periconceptional use of folic
acid supplements (FAS) to prevent neural
tube defects (NTDs) have been well
established since the early 1990s.1 2 Health
authorities recommend that all women who
plan to become pregnant should take a daily
dose of 400 µg FAS and appropriate dietary
folate intake from before conception to the
third month of pregnancy to reduce the risk
of NTDs, while not exceeding the tolerable
upper intake level of 1000 µg/day.3 An
exception is made for those women with dia-
betes, epilepsy and history of NTDs, who are
recommended to take a daily dose of
5000 µg FAS.4 Although FAS are safe and
almost free of toxicity, a few studies have
drawn attention to the possible adverse
effects of using high doses throughout preg-
nancy5–8 and at other stages of life.9
The interest in the health implications of
taking FAS has increased recently. Regarding
pregnancy, several studies have suggested that
FAS use may be an important protective
factor for some birth outcomes such as pla-
cental abruption, spontaneous abortion, still-
birth, preterm delivery, adverse fetal growth
and preeclampsia.10 11 FAS use during preg-
nancy has been also associated with protec-
tion against impaired neurodevelopment,12 13
but we have recently observed that FAS
dosages above the recommendation might
affect psychomotor development at 1 year of
age.8 Several studies have found a relationship
between FAS and allergic disorders or
asthma in childhood,14 although a recent
meta-analysis does not provide a conclusive
Strengths and limitations of this study
▪ We assessed dietary folate intake and folic acid
supplement, using a validated food frequency
questionnaire in pregnant Spanish women.
▪ This was a population-based cohort study.
▪ Participation rates were not high and non-
participation might limit the generalisation of
some results.
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association.15 Although FAS might reduce the risk of
several harmful pregnancy outcomes and childhood pro-
blems, many questions still remain open on the potential
effects of using high dosages of FAS at different periods
during pregnancy.
In this sense, most studies have focused on monitoring
dietary folate intake and FAS in the periconceptional
period,16–19 and only a few have assessed the use of FAS
after the time period around neural tube closure.20
Thus, research into maternal folate intake and the use
of high dosages of FAS during pregnancy is necessary
for the clariﬁcation of the possible effects in birth out-
comes and in childhood health.12–15 In this study, we
use data from pregnant women participating in a multi-
centre prospective mother–child cohort study in Spain,
to examine the use of low (non-use and <400 μg/day)
and high dosages (≥1000 μg/day) of FAS in pregnant
women in Spain from 3 months before conception to
the third month of pregnancy and from the fourth to
seventh month of pregnancy. We also explore factors
associated with the use of these low and high dosages of
FAS in the two periods.
MATERIALS AND METHODS
Population
We use data from 2332 pregnant women recruited in
the multicentre population-based mother–child cohort
INMA Project (INfancia y Medio Ambiente (Childhood
and Environment)) between 2003 and 2008 in four dif-
ferent regions of Spain with a common protocol:
Valencia, Sabadell (Catalonia), Asturias and Guipuzcoa
(Basque Country).21 Women were enrolled during their
ﬁrst antenatal care visit to the main public hospital or
health centre of reference. A total of 2644 women who
fulﬁlled the inclusion criteria (≥16 years old, singleton
pregnancy, intention to deliver at the reference hospital,
no communication handicap and no assisted pregnancy)
agreed to participate. Excluding the women who with-
drew from the study, those lost to follow-up and those
who had an induced or spontaneous abortion, or who
had fetal deaths (n=138), a total sample of 2506 women
delivered a live infant between May 2004 and August
2008. After excluding participants with missing data for
relevant variables, 2332 (93.1%) were included in the
present analysis. All participants provided informed
consent, and the ethics committees of the centres
involved in the study approved the research protocol.
Study variables
Assessment of dietary folate intake and FAS use
FAS and dietary folate were retrospectively assessed by
personal interviews at two time points in pregnancy: at
10–13 weeks and at 28–32 weeks; more details about
these intakes were described previously.22 Dietary folate
intake was determined using a 101-item, semiquantitative
food frequency questionnaire (FFQ), covering intakes in
two periods. The ﬁrst period included intakes from the
last menstrual period until the third month of pregnancy,
and the second period covered intakes from the fourth
month to the seventh month of pregnancy. The FFQ was
an adapted version of the Willett questionnaire,23 vali-
dated and developed for Spanish pregnant women in
Valencia.24 In a validation study of the FFQ carried out
within the same population of pregnant women in the
third month of pregnancy, the correlation coefﬁcient
between serum folate and the intake of dietary folate and
FAS was satisfactory, r=0.53 (p<0.001).24
Folate content of food items was primarily obtained
from food composition tables of the US Department of
Agriculture25 and other tables published for Spanish
foods.26 In Spain, folate fortiﬁcation is not mandatory,
thus we obtained the folate content of foods from non-
fortiﬁed foods; except for cereals, owing to the main
brands usually fortifying them. The consumption level
of FAS or vitamin/mineral preparations containing FAS
was collected using a structured questionnaire. FAS were
estimated based on supplement brand name and com-
position, daily dose and timing of consumption. There
were three main sources of FAS in Spain: speciﬁc single
folic acid preparations with content from 400 μg
(Zolico) to 10 000 μg (ASPOL); supplements of levofoli-
nate or calcium folinate with content between 2500 μg
(Folaxin 2.5®) and 15 000 μg/day (Lederfoli); and mul-
tivitamins with folic acid content between 75 μg
(Calcinaralobs) and 1000 μg (Gestamater). With this
information, mean daily FAS intake was estimated as the
mean of FAS intake in two periods: the ﬁrst period
included the information of FAS from 3 months before
conception to the third month of pregnancy (interview
at 10–13 weeks) and the second period included the
information of FAS from fourth to seventh month of
pregnancy (interview at 28–32 weeks). FAS intake in the
two periods was classiﬁed into three categories: <400
(including no use), 400–999 and ≥1000 µg/day.
Covariates
Information on covariates was obtained from question-
naires completed by personal interviews in the ﬁrst and
third trimester of pregnancy. The sociodemographic
characteristics considered were: maternal age, maternal
and paternal education level (primary school or less,
secondary school and university studies), lifestyle vari-
ables such as tobacco smoking (yes or no), alcohol con-
sumption (yes or no) in the ﬁrst trimester of pregnancy,
and self-reported pre-pregnancy body mass index calcu-
lated in kg/m2 and classiﬁed as <25, 25–29.9 (over-
weight) and ≥30 (obesity). Relevant data about
obstetrics such as number of previous pregnancies (0
and ≥1), unplanned pregnancy (yes or no), previous
abortion (yes or no) and visiting a private gynaecologist
in the ﬁrst trimester (yes or no) were also collected.
Statistical analysis
Descriptive analysis of sociodemographic, lifestyle and
obstetric characteristics of the pregnant women was
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performed for the four areas of study. We also described
the dietary folate and FAS intake overall and by geo-
graphical area using geometrical mean, mean and SDs.
We used the analysis of variance test for quantitative vari-
ables and the χ2 test for qualitative variables.
Predictors of the use of low (<400 µg/day, including
non-users) and high (≥1000 µg/day) dosages of FAS
from preconception to the third month, from the fourth
to the seventh month of pregnancy and in the entire
pregnancy were explored using multivariate multinomial
logistic regression (relative risk ratio: RRR): low-dose or
high-dose categories were compared to the recom-
mended dose (400–999 µg/day) adjusted for all other
covariates by study areas. We used meta-analysis to obtain
combined estimates for the four cohorts. Heterogeneity
was quantiﬁed by means of the (I2) statistic and p value
of heterogeneity test.27 With levels above 50%, the
random-effects model was applied to obtain combined
estimates and the ﬁxed effect meta-analysis model when
I2<50%. Statistical analyses were conducted with R 3.0.0
(R Foundation for Statistical Computing, Vienna,
Austria; http://www.r-project.org).
RESULTS
Table 1 shows the sociodemographic, lifestyle and obstet-
ric characteristics of the pregnant women. Signiﬁcant
differences among geographical areas were observed for
most variables although not for parity and previous abor-
tions. Half of the pregnant women were above 30 years
of age (Asturias showed the highest proportion, 59.7%,
and Valencia the lowest proportion, 43.2%). Of the
women, 34.4% reported having pursued university
studies. Tobacco smoking and alcohol consumption
during the ﬁrst trimester of pregnancy were reported by
18.1% and 29.9% of the women, respectively. The preva-
lence of pre-pregnancy obesity was 8.0%. A total of
16.7% of pregnancies were unplanned and previous
abortions were reported by 23.5% of the women.
The mean daily folate intake was similar in the two
periods of pregnancy, 307.8 and 304.7 µg/day, respect-
ively. The main food group sources of dietary folate
intake among the pregnant women in both periods of
pregnancy were vegetables (22.8%), fruits (15.7%),
legumes (10.5%), dairy products (8.6%) and cereals/
pasta (7.0%). Individually, the major contributing foods
to dietary folate intake were legumes (10.5%), lettuce
(8.4%), oranges (5.5%), bread (5.5%) and cereals
(5.5%).
Figure 1 shows the proportion of women using FAS
during pregnancy. The percentage of women using FAS
in preconception, the ﬁrst, second and third month of
pregnancy was 22.8%, 30.4%, 57.4% and 85.8%, respect-
ively. The proportion of women using FAS in the peri-
conceptional period was similar in the four geographical
areas although signiﬁcant differences were noted after-
wards: women in Valencia and Asturias continued using
FAS after the third month (84% and 95%, respectively),
while most women in Guipuzcoa and Sabadell stopped
(approximately 10% continued). Overall, 149 of the
women did not take FAS at any time during pregnancy;
most were from Sabadell and Guipuzcoa (89%).
Considering the entire pregnancy, approximately
one-third of the women reported the use of high
dosages of FAS (≥1000 µg/day), although this propor-
tion varied by geographical area: Asturias and
Guipuzcoa showed higher percentages of women using
FAS dosages ≥1000 µg/day than women from Sabadell
and Valencia (data not show). The major sources of
high dosages of FAS (≥1000 µg/day) were speciﬁc single
folic acid preparations such as ACFOL (5000 µg/day) or
ASPOL (10 000 µg/day).
Overall, during the periconceptional stage, 57% of
pregnant women used low FAS dosages (<400 µg/day,
including no use), and 29% of women used high FAS
dosages (≥1000 µg/day). In this period, the mean daily
intake of FAS was 433.0 µg/day for women classiﬁed as
taking FAS dosages of 400–999 µg/day, 141.8 µg/day for
women taking FAS dosages <400 µg/day and 3104.6 for
women taking dosages of ≥1000 µg/day. Table 2 shows
multivariate analyses for all the cohorts combined, in
the ﬁrst period. Tobacco smoking (RRR=1.63) and
alcohol intake (RRR=1.40) in the ﬁrst trimester of preg-
nancy, unplanned pregnancy (RRR=4.20), previous preg-
nancies (RRR=1.44) and previous abortions (RRR=0.58,
lower use of high FAS dosages among those with previ-
ous abortions) were signiﬁcantly associated with the use
of low FAS dosages in the periconceptional period.
Unplanned pregnancy (RRR=2.66), previous abortions
(RRR=0.68) and alcohol intake (RRR=1.42) were signiﬁ-
cantly associated with the use of high FAS dosages.
These results were homogeneous among study areas
(I2<50%).
The proportion of women using low FAS dosages after
the periconceptional period was 55% and 17% of
women took high FAS dosages after the periconcep-
tional period. In this period, the mean daily intake of
FAS was 511.7 µg/day for women classiﬁed as taking FAS
dosages of 400–999 µg/day, 59.1 µg/day for women
taking FAS dosages <400 µg/day and 4095.2 for women
taking dosages of ≥1000 µg/day.
Table 3 shows multivariate analyses for all cohorts
combined for the second period (4th–7th month). In
the second period, only tobacco smoking was signiﬁ-
cantly associated with the use of high FAS dosages
(RRR=0.67); no additional signiﬁcant predictors of the
use of low and high FAS dosages were found in the
second period.
DISCUSSION
In this study, we show that a low percentage of pregnant
women used FAS in preconception (23%), although the
percentage of use increased to reach most of the women
in the third month of pregnancy (86%). This pattern
was consistent in the four areas of the study, although
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Table 1 Sociodemographic, lifestyle and obstetrics characteristics among pregnant women, from the INMA Project, Spain (2003–2008)
All cohorts (n=2332) Asturias (n=434) Guipuzcoa (n=521) Sabadell (n=597) Valencia (n=780) p Value*
Maternal age (>30 years), % (n) 50.1 (1168) 59.7 (259) 55.1 (287) 47.1 (281) 43.2 (341) <0.001
Maternal education, % (n)
Primary school or less 24.0 (560) 16.8 (73) 11.3 (59) 28.0 (167) 33.5 (261) <0.001
Secondary school 41.6 (970) 45.2 (196) 35.3 (184) 42.9 (256) 42.8 (334)
University studies 34.4 (802) 38.0 (165) 53.4 (278) 29.1 (174) 23.7 (185)
Paternal education, % (n)
Primary school or less 35.5 (829) 28.8 (125) 24.4 (127) 36.0 (215) 46.4 (362) <0.001
Secondary school 44.5 (1037) 49.1 (213) 50.5 (263) 43.2 (258) 38.8 (303)
University studies 20.0 (466) 22.1 (96) 25.1 (131) 20.8 (124) 14.7 (115)
Tobacco smoking (during first
trimester), % (n)
18.1 (423) 17.7 (77) 11.9 (62) 15.2 (91) 24.7 (193) <0.001
Alcohol intake (during first
trimester), % (n)
29.9 (698) 21.9 (95) 36.1 (188) 30.0 (179) 30.3 (236) <0.001
Pre-pregnancy BMI in kg/m2, % (n)
<25 73.3 (1710) 69.1 (300) 80.4 (419) 72.2 (431) 71.8 (560) 0.001
25.0–29.9 18.7 (436) 22.6 (98) 14.6 (76) 19.6 (117) 18.6 (145)
≥30 8.0 (186) 8.3 (36) 5.0 (26) 8.2 (49) 9.6 (75)
Unplanned pregnancy, n (%) 16.7 (389) 12.4 (54) 9.6 (50) 15.6 (93) 24.6 (192) <0.001
Parity (≥1), n (%) 43.3 (1009) 38.2 (166) 44.9 (234) 43.2 (258) 45.0 (351) 0.112
Previous abortions (yes), n (%) 23.5 (549) 23.7 (103) 20.5 (107) 25.5 (152) 24.0 (187) 0.270
Private gynaecology (visit during
first trimester), n (%)
34.2 (797) 50.2 (218) 26.1 (136) 29.5 (176) 34.2 (267) <0.001
Dietary folate intake in µg/day 1st
period1, GM (mean, SD)
293.5 (307.8, 96.3) 305.0 (320.6, 103.5) 302.5 (314.6, 90.3) 285.3 (298.2, 90.8) 287.6 (303.3, 99.3) <0.001
Folic acid supplements intake in
µg/day 1st period1, GM (mean,
SD)
450.9 (1029.4, 1626.6) 610.0 (1180.8, 1613.0) 585.5 (1331.9, 1788.1) 353.4 (770.6, 1401.3) 390.8 (941.0, 1643.7) <0.001
Dietary folate intake in µg/day
2nd period2, GM (mean, SD)
290.4 (304.7, 96.1) 296.2 (312.1, 100.9) 303.6 (313.0, 80.2) 289.8 (302.4, 90.2) 279.2 (296.8, 106.4) 0.007
Folic acid supplements intake in
µg/day 2nd period2, GM (mean,
SD)
631.1 (870.6, 1683.8) 1014.7 (1975.2, 2267.5) 666.4 (541.5, 1523.2) 409.3 (216.1, 843.1) 524.7 (977.6, 1561.5) <0.001
1: First period covers the months from preconception to the first trimester of pregnancy; 2: second period covers the months from the first to the third trimester.
*p Value from χ2 test (categorical variables) and analysis of variance (continuous variables).
GM, Geometric mean.
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signiﬁcant differences emerged later; most of the
women in Valencia and Asturias continued using FAS
after the third month while most of the women in
Guipuzcoa and Sabadell stopped using them. We also
found that nearly one-third of the women used high
dosages of FAS (≥1000 µg/day). The use of high FAS
dosages in the ﬁrst period, from preconception to the
third month, was signiﬁcantly associated with unplanned
pregnancy and previous spontaneous abortion (lower
use of high FAS dosages among those with previous
abortions).
The mean daily dietary intake in the present study was
similar to that reported in other European studies28–31—
below the recommended dietary intake for pregnant
women. The unsatisfactory intake among pregnant
women might be related to the lack of knowledge on
food rich in this nutrient, as shown in a study conducted
in a Mediterranean population, in which only 40% of
respondents could identify one food rich in folate.32
Regarding the use of FAS, the results of this study are in
accordance with previous studies conducted in Spain
and Portugal, where around 70% of pregnant women
did not take FAS before pregnancy,31 33 34 and slightly
higher than in other European studies.17–20 30 The con-
siderable number of women who did not use FAS may
be explained in part by the fact that they were not aware
of being pregnant and, therefore, were not informed of
the beneﬁts of FAS at the beginning of their pregnancy.
Based on our results, it seems that when women are
aware of their pregnancy, they increase their use of FAS,
particularly in the second and third month of
pregnancy.
We observed two different patterns of FAS use after
the third month in the four geographical areas of the
study. Women in Valencia and Asturias continued with
the use of FAS while women in Guipuzcoa and Sabadell
mostly abandoned the use of supplements. We have no
clear explanation for the two different patterns of FAS
use observed between areas, although it could be
related, in part, to the different policy statements of
regional scientiﬁc societies about FAS use, as has been
observed for other nutrients such as iodine
supplementation.35
The large number of pregnant women reporting the
use of high FAS dosages during pregnancy has also been
reported in two other previous studies in Spain.16 36 A
possible cause could be related to medical reasons since
women with diabetes, epilepsy or history of NTDs before
pregnancy are usually recommended to take FAS
dosages of 5000 µg/day in the periconceptional period.
However, in our study, the number of women with these
pathologies was low (<1%). Moreover, the use of these
high dosages of FAS was unnecessarily maintained after
the third month of pregnancy. The percentage of
women taking high dosages of FAS in this study was
lower than that observed in a previous study in Spain,16
which may be explained in part by the debate and the
controversy on the consequences of a higher than
recommended FA supplementation.37–39 We believe that
the percentage of women taking high FAS dosages still
remains high, and further studies are needed to
monitor the use of FAS during pregnancy and the
potential harmful effects that have been shown
recently.5–8
Several associations were found with the use of high
FAS dosages. The positive association with unplanned
pregnancy and the negative association with previous
spontaneous abortion have been found in other
Figure 1 Folic acid supplements use among 2422 participants in all cohorts of the INMA Project, Spain (2003-2008).
Percentage by months of pregnancy.
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studies.17 19 20 40–43 Women who have planned their
pregnancy and those who had undergone a previous
spontaneous abortion may have higher awareness of the
beneﬁts of recommended intake and FAS dosages (400–
999 µg/day) in pregnancy. The association with tobacco
smoking, alcohol intake and parity found in our study
have also been found in other studies.19 42 43 It is pos-
sible that pregnant women with better lifestyles had a
better compliance with the recommended dosages of
FAS than those with less healthy lifestyles (eg, alcohol
drinkers). However, more studies are required to
conﬁrm these associations with the use of high dosages
of FAS during the periconceptional period in order to
implement public health actions.
This study has several strengths. The prospective
design minimises selection and recall bias. We assessed
dietary folate intake and FAS use prospectively in differ-
ent geographical areas of Spain with a wide range of
consumption, using a validated FFQ in the same study
population. Our study also has some limitations. This
was a population-based cohort study and non-
participation might limit the generalisability of some
results; however, when the sociodemographic character-
istics of participants and non-participants were
Table 2 Pooled RRR* and 95% CI of folic acid supplement doses in the periconceptional period (first period)† of pregnancy
among pregnant women, from the INMA Project, Spain (2003–2008)
Women who took
FAS, n (%)
Folic acid supplement use (in µg/day) during the first period†
400–999
(mean=433.0)
<400, included non use
(mean=141.8) ≥1000 (mean=3104.6)
329 (14%) 1336 (57%) 666 (29%)
n n RRR* (95% CI) I2, %‡ n RRR* (95% CI) I2, %‡
Maternal age, (years)
≤30 161 722 1.00 281 1.00
>30 168 614 0.90 (0.58 to 1.40) 58.4 385 1.31 (0.82 to 2.10) 58.5
Maternal education
Primary school or less 65 373 1.00 122 1.00
Secondary school 124 563 1.06 (0.73 to 1.52) 0.0 283 1.31 (0.88 to 1.94) 0.0
University studies 140 400 0.66 (0.44 to 0.98) 27.3 261 0.91 (0.59 to 1.39) 24.4
Paternal education
Primary school or less 96 525 1.00 208 1.00
Secondary school 164 557 0.70 (0.51 to 0.95) 0.0 316 0.82 (0.59 to 1.15) 0.0
University studies 69 254 0.97 (0.65 to 1.45) 0.0 142 1.00 (0.65 to 1.54) 0.0
Tobacco smoking†
No 289 1061 1.00 558 1.00
Yes 40 275 1.63 (1.11 to 2.39) 0.0 108 1.36 (0.90 to 2.07) 0.0
Alcohol consumption†
No 251 923 1.00 460 1.00
Yes 78 413 1.40 (1.02 to 1.92) 39.1 206 1.42 (1.01 to 1.98) 19.2
Pre-pregnancy BMI
<25 241 969 1.00 499 1.00
25–29.9 60 253 0.95 (0.67 to 1.33) 0.0 123 0.90 (0.62 to 1.30) 19.9
≥30 28 114 0.89 (0.55 to 1.44) 12.4 44 0.79 (0.46 to 1.36) 0.0
Planned pregnancy
Yes 312 1051 1.00 579 1.00
No 17 285 4.20 (2.47 to 7.12) 5.0 87 2.66 (1.52 to 4.65) 0.0
Parity
0 209 744 1.00 369 1.00
≥1 120 592 1.44 (1.08 to 1.91) 0.0 297 1.33 (0.98 to 1.80) 0.0
Previous abortions
No 231 1047 1.00 504 1.00
Yes 98 289 0.58 (0.43 to 0.77) 45.5 162 0.68 (0.50 to 0.94) 42.0
Private gynaecologist†
No 189 923 1.00 423 1.00
Yes 140 413 0.78 (0.52 to 1.17) 53.0 243 0.88 (0.42 to 1.88) 84.2§
*Cohort-specific multinomial logistic models were combined using meta-analysis, the models were adjusted by all variables in the table.
†During the periconceptional stage from the preconception to the third month.
‡We used the results from fixed effect meta-analysis model when I2 was <50% and from the random effects meta-analysis model when I2 was
>50%.
§P Cochran <0.05 from test of heterogeneity.
BMI, body mass index; RRR, relative risk ratio.
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compared, no signiﬁcant differences were found except
for working status and age, with a higher proportion of
working women and slightly higher mean age among
participants. Despite some study limitations, if con-
ﬁrmed, our ﬁndings should have implications for future
public health policies and strategies to promote
adequate use of FAS at the recommended dosages
during the periconceptional period, and to prevent the
use of unnecessary dosages in other periods.
In conclusion, this study shows that the use of FAS
among pregnant women in Spain is far from satisfactory.
Most women did not follow recommendations for FAS
during pregnancy, using dosages either below or above
the current recommendation. Previous pregnancies,
tobacco smoking, alcohol consumption, unplanned
pregnancies and no previous abortions were associated
with FAS use below 400 µg/day in the periconceptional
period. Alcohol consumption, unplanned pregnancy
and previous spontaneous abortion were also predictors
of the use of high dosages of FAS at this initial stage.
These ﬁndings should be further monitored; mean-
while, public health strategies should be planned to
increase public awareness of the appropriate pericon-
ceptional use of FAS and to encourage health profes-
sionals to prevent the use of FAS dosages above or below
the current recommendations.
Table 3 Pooled RRR* and 95% CI of folic acid supplements doses in the second period† of pregnancy among pregnant
women, from the INMA Project, Spain (2003–2008)
Women who took FAS,
n (%)
Folic acid supplement use (in µg/day) during the second period†
400–999
(mean=511.7)
<400, included non use
(mean=59.1) ≥1000 (mean=4095.2)
657 (28%) 1275 (55%) 394 (17%)
n n RRR* (95% CI) I2 (%)‡ n RRR* (95% CI) I2 (%)‡
Maternal age (years)
≤30 343 653 1.00 164 1.00
>30 314 622 1.05 (0.61 to 1.82) 77.2§ 230 1.54 (0.92 to 2.59) 61.8§
Maternal education
Primary school or less 194 284 1.00 82 1.00
Secondary school 274 523 1.29 (0.97 to 1.72) 0.0 168 1.26 (0.88 to 1.80) 0.0
University studies 189 468 1.30 (0.92 to 1.85) 0.0 144 1.20 (0.54 to 2.66) 65.4§
Paternal education
Primary school or less 254 441 1.00 133 1.00
Secondary school 282 568 0.89 (0.69 to 1.15) 0.0 182 0.94 (0.68 to 1.29) 0.0
University studies 121 266 0.78 (0.54 to 1.12) 0.0 79 0.80 (0.52 to 1.22) 25.3
Tobacco smoking†
No 512 1088 1.00 332 1.00
Yes 145 187 0.70 (0.42 to 1.18) 61.7¶ 62 0.67 (0.47 to 0.96) 8.1
Alcohol consumption†
No 426 767 1.00 252 1.00
Yes 231 508 1.01 (0.80, 1.28) 0.0 142 1.09 (0.82 to 1.45) 0.0
Pre-pregnancy BMI
<25 456 970 1.00 281 1.00
25–29.9 138 217 0.82 (0.62 to 1.09) 0.0 80 0.89 (0.63 to 1.25) 0.0
≥30 63 88 0.70 (0.47 to 1.06) 11.5 33 0.87 (0.53 to 1.43) 0.0
Planned pregnancy
Yes 531 1073 1.00 336 1.00
No 126 202 1.05 (0.78 to 1.41) 0.0 58 0.90 (0.61 to 1.32) 0.0
Parity
0 381 717 1.00 223 1.00
≥1 276 558 1.08 (0.85 to 1.38) 35.5 171 0.99 (0.74 to 1.33) 76.3§
Previous abortions
No 504 974 1.00 301 1.00
Yes 153 301 1.07 (0.82 to 1.41) 7.8 93 0.95 (0.69 to 1.31) 10.9
Private gynaecologist¶
No 404 880 1.00 245 1.00
Yes 253 395 0.88 (0.60 to 1.27) 54.9 149 0.79 (0.28 to 2.21) 91.3§
*Cohort-specific multinomial logistic models were combined using meta-analysis, the models were adjusted by all variables in the table.
†Second period covers the months from the fourth to the seventh month of pregnancy.
‡We used the results from fixed effect meta-analysis model when I2 was <50% and from the random effects meta-analysis model when I2 was
>50%.
§p Cochran <0.05 from test of heterogeneity.
¶During the periconceptional stage (first period) from the preconception to the third month.
BMI, body mass index; RRR, relative risk ratio.
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